Loading company
Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Exelixis, Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$68.99-1.2%Nov 13 close
Figures through October 2, 2026, from the 10-Q filed October 29, 2026
Exelixis sells cancer medicines, chiefly Cabometyx, to U.S. wholesalers and specialty pharmacies, and earns royalties from partners selling cabozantinib abroad.